Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials
Open accessAbstract
Daratumumab has shown clinical benefit in multiple myeloma. We aimed to evaluate the safety and efficacy of adding daratumumab to backbone anti-myeloma treatments. Systematic search was performed up to August 2021 to identify randomised controlled trials comparing the outcomes of backbone therapy with and without daratumumab in relapsed/refractory and newly diagnosed myeloma (RRMM and NDMM, respectively). Odds ratios (ORs) and hazard ratios (HRs) were calculated with 95% confidence intervals (CIs). Primary outcomes were death or disease progression, minimal residual disease (MRD) negativity, and stringent complete response (sCR). Secondary outcomes were complete response or better and safety endpoints prespecified in the study protocol: PROSPERO (CRD42020222904). In NDMM, MRD negativity [OR = 3.61 (CI 2.33–5.61)] and sCR [OR = 2.29 (CI 1.49–3.51)] were more likely and death or disease progression [HR = 0.47 (CI 0.39–0.57)] was less likely to occur with daratumumab compared to control. Regarding RRMM, MRD negativity [OR = 5.43 (CI 2.76–10.66)] and sCR [OR = 3.08 (CI 2.00–4.76)] were more likely and death or disease progression was less likely [HR = 0.50 (CI 0.37–0.67)] with daratumumab compared to control. The addition of daratumumab has shown high clinical efficacy and acceptable toxicity profile for the treatment of NDMM and RRMM regarding the endpoints examined.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Absence of minimal residual disease has been associated with improved overall survival and progression-free survival in patients with myeloma.
“Such absence of minimal residual disease has been associated with improved overall survival and progression-free survival in patients with myeloma.14-16”
From Teclistamab in Relapsed or Refractory Multiple Myeloma (2022) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283 · see citing works
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · see citing works
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 33,583 · see citing works
Interrater reliability: The kappa statistic
McHugh, M. L. (2012) · Biochemia Medica · doi:10.11613/bm.2012.031 · Cited by 19,877 · see citing works
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522 · see citing works
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · see citing works
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,027 · see citing works
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
Mateos, M., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A. J., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., Kaplan, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 991 · see citing works
Moreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31240-1 · Cited by 979 · see citing works
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 802 · see citing works
Multiple myeloma epidemiology and survival: A unique malignancy
Kazandjian, D. G. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.11.004 · Cited by 765 · see citing works
Voorhees, P. M., Kaufman, J. L., Laubach, J. P., Sborov, D. W., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R. W., Costa, L. J., Anderson, L. D., et al. (2020) · Blood · doi:10.1182/blood.2020005288 · Cited by 698 · see citing works
Mateos, M., Cavo, M., Bladé, J., Dimopoulos, M. A., Suzuki, K., Jakubowiak, A. J., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32956-3 · Cited by 447 · see citing works
Dimopoulos, M., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30734-0 · Cited by 430 · see citing works
Perrot, A., Lauwers‐Cancès, V., Corre, J., Robillard, N., Hulin, C., Chrétien, M., Dejoie, T., Mahéo, S., Stoppa, A., Pegourié, B., et al. (2018) · Blood · doi:10.1182/blood-2018-06-858613 · Cited by 420 · see citing works
Dimopoulos, M. A., Terpos, E., Boccadoro, M., Delimpasi, S., Beksac, M., Katodritou, E., Moreau, P., Baldini, L., Symeonidis, A., Bila, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00128-5 · Cited by 344 · see citing works
Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents
Chanan-Khan, A. A., & Giralt, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4250 · Cited by 194 · see citing works
Dong, C., & Hemminki, K. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1998 · Cited by 179 · see citing works
Dong, C., & Hemminki, K. (2001) · British Journal of Cancer · doi:10.1038/sj.bjc.6691998 · Cited by 176 · see citing works
Kapoor, P., Kumar, S. K., Dispenzieri, A. A., Lacy, M. Q., Buadi, F. K., Dingli, D., Russell, S. J., Hayman, S. R., Witzig, T. E., Lust, J. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.0086 · Cited by 162 · see citing works
Giri, S., Grimshaw, A. A., Bal, S., Godby, K. N., Kharel, P., Djulbegović, B., Dimopoulos, M. A., Facon, T. T. F., Usmani, S. Z., Mateos, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4338 · Cited by 107 · see citing works
Merrill, R. M., & Dearden, K. A. (2004) · Cancer Causes & Control · doi:10.1007/s10552-004-1324-5 · Cited by 83 · see citing works
Second primary malignancies in multiple myeloma: A review
Poh, C., Keegan, T. H. M., & Rosenberg, A. S. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100757 · Cited by 75 · see citing works
Daratumumab for the Treatment of Multiple Myeloma
Plesner, T., & Krejcik, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01228 · Cited by 68 · see citing works
High-risk Multiple Myeloma: Definition and Management
Joseph, N. S., Gentili, S., Kaufman, J. L., Lonial, S., & Nooka, A. K. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.018 · Cited by 42 · see citing works
Weisel, K. C., Spencer, A. G., Lentzsch, S., Avet‐Loiseau, H., Mark, T. M., Špıčka, I., Masszi, T., Lauri, B., Levin, M., Bosi, A., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00948-5 · Cited by 42 · see citing works
Lu, J., Fu, W., Li, W., Hu, J., An, G., Wang, Y., Fu, C., Chen, L., Jin, J., Cen, X., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.04.012 · Cited by 38 · see citing works
Bahlis, N. J., Facon, T. T. F., Usmani, S. Z., Kumar, S. K., Plesner, T., Orlowski, R. Z., Touzeau, C., Basu, S., Nahi, H., Hulin, C., et al. (2019) · Blood · doi:10.1182/blood-2019-123426 · Cited by 37 · see citing works
Daratumumab-based induction therapy for multiple myeloma: A systematic review and meta-analysis
Chong, L. L., Soon, Y. Y., Soekojo, C. Y., Ooi, M. G. M., Chng, W. J., & Mel, S. D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103211 · Cited by 32 · see citing works
Use of daratumumab in high risk multiple myeloma: A meta‐analysis
Premkumar, V. J., Pan, S. M., Lentzsch, S., & Bhutani, D. (2020) · eJHaem · doi:10.1002/jha2.47 · Cited by 27 · see citing works
Evolving Role of Daratumumab: From Backbencher to Frontline Agent
Jain, A., & Ramasamy, K. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.03.010 · Cited by 20 · see citing works
Kaufman, J. L., Dimopoulos, M. A., White, D. J., Benboubker, L., Cook, G., Leiba, M., Morton, J., Ho, P. J., Kım, K., Takezako, N., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00375-2 · Cited by 18 · see citing works
Wang, Y., Li, Y., & Chai, Y. (2021) · Journal of International Medical Research · doi:10.1177/03000605211038135 · Cited by 17 · see citing works
When to Use Targeted Therapy for the Treatment of Follicular Lymphoma
Nastoupil, L. J. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00617-5 · Cited by 10 · see citing works
Mohyuddin, G. R., Sigle, M., Chandrasekar, V. T., Aziz, M., Abdallah, A.-O. A., Shune, L. O., & McClune, B. L. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1772475 · Cited by 9 · see citing works
Xu, W., Li, D., Sun, Y., Ran, X., Wang, B., Wu, W., Sheng, Z., & Liu, L. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13317 · Cited by 8 · see citing works
Monoclonal Antibody Therapy in Multiple Myeloma: Where do we Stand and Where Are We Going?
Thanendrarajan, S., Davies, F. E., Morgan, G. J., Schinke, C., Mathur, P., Heuck, C. J., Zangari, M., Epstein, J., Yaccoby, S., Weinhold, N., et al. (2016) · Immunotherapy · doi:10.2217/imt.15.118 · Cited by 6 · see citing works
Cao, C., Zhou, X., & Ma, Q. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.797 · Cited by 5 · see citing works
Htut, T. W., Quick, D. P., Win, M. A., Swarup, S., Sultan, A., Ball, S., Phyu, E. M., Yu, N. H., Han, M. M., Myat, Y. M., et al. (2019) · Blood · doi:10.1182/blood-2019-123156 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Teclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269 · see citing works
Treatment horizon in multiple myeloma
Soekojo, C. Y., & Chng, W. J. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13840 · Cited by 35 · see citing works
Filho, J. T. D. S., Cantadori, L. O., Crusoé, E. D. Q., Hungria, V., & Maiolino, Â. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01253-5 · Cited by 14 · see citing works
Lu, Y., Zhou, F., Cheng, D., Xie, M., Yan, X., Xue, Y., Yang, Q., Jia, R., Zhong, L., Yang, L., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1240318 · Cited by 9 · see citing works
Lonial, S., Bowser, A. D., Chari, A., Costello, C. L., Krishnan, A. Y., & Usmani, S. Z. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.07.001 · Cited by 8 · see citing works
Mian, A., Naqvi, S. A. A., Ayaz, A., Husnain, M., Aljama, M. A., Mohyuddin, G. R., Koehn, K., Mohan, M., Riaz, I. B., & Chakraborty, R. (2023) · Leukemia Research · doi:10.1016/j.leukres.2023.107324 · Cited by 7 · see citing works
A real‑world pharmacovigilance study of FDA adverse event reporting system events for daratumumab
Yun, X., Zhou, Y., Wu, D., Liu, Y., & Wu, Q. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2328321 · Cited by 7 · see citing works
Zayad, A., Magee, G., Mansour, R. A., Chang, M., Ahmed, N., Mushtaq, M. U., Paul, B. A., Green, K. M., Davis, J. A., Skikne, B., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.08.017 · Cited by 5 · see citing works
Ailawadhi, S., Cheng, M., Cherepanov, D., DerSarkissian, M., Stull, D. M., Hilts, A., Chun, J., Duh, M. S., & Sanchez, L. J. (2024) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2024.101078 · Cited by 4 · see citing works
Az elérhető gyógyulás küszöbén: innovációk a myeloma multiplex kezelésében
Tóth, T., & Alizadeh, H. (2024) · Orvosi Hetilap · doi:10.1556/650.2024.33036 · Cited by 3 · see citing works
Self-citationPadmaraju, K., Kelly, K., Jakubowiak, A. J., & Derman, B. A. (2024) · The Oncologist · doi:10.1093/oncolo/oyae158 · Cited by 3 · see citing works
He, J., Berringer, H., Heeg, B. M. S., Ruan, H., Kampfenkel, T., Dwarakanathan, H. R., Johnston, S. S., Mendes, J., Lam, A., Bathija, S., et al. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02226-x · Cited by 3 · see citing works
Lin, Z., Dong, R., Zhang, W., Liu, R., Fu, B., & He, A. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2512031 · Cited by 3 · see citing works
Adam, Z., Pour, L., Krejčí, M., Zeman, D., Vlčková, E., Krtička, M., Šlampa, P., Štěpánková, S., Romanová, G., Adamová, Z., et al. (2022) · Onkologie · doi:10.36290/xon.2022.054 · Cited by 1 · see citing works
Alrasheed, M. A., Alsuhibani, A. A., Balkhi, B. S., & Guo, J. J. (2023) · Healthcare · doi:10.3390/healthcare11162265 · Cited by 1 · see citing works
Al-Ali, N. O., Pinczés, L. I., Farkas, K., Kerekes, G., Illés, Á., & Váróczy, L. (2024) · Journal of Hematology · doi:10.14740/jh1256 · Cited by 1 · see citing works
Channar, A., Naqvi, S. A. A., Khan, M. A., Bibi, A., Saxena, A., Tripathi, N., Iftikhar, A., Raina, A., Khakwani, K. Z. R., Riaz, I. B., et al. (2025) · Cancer Reports · doi:10.1002/cnr2.70171 · Cited by 1 · see citing works
Tan, C. J., Kacerek, D., Kampirapawong, N., Godara, A., & Chaiyakunapruk, N. (2025) · Cancer Medicine · doi:10.1002/cam4.70585 · Cited by 1 · see citing works
Myeloma multiplex: a jelen kihívásai és a korszerű ellátás feltételei I.
Mór, Z., Tóth, Á., Alizadeh, H., Borbényi, Z., Egyed, M., Illés, Á., Masszi, T., & Mikala, G. (2024) · Hematológia–Transzfuziológia · doi:10.1556/2068.2024.00190
Self-citationMoustafa, D. A., Shafei, L., Sulaiman, R., Yassin, M. A., Abushanab, D., Algarabli, Y., & Al‐Badriyeh, D. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552241290452
Chen, Y., Cai, Q., Qiu, Z., Geng, H., Li, Y., Zhan, R., & Zheng, Z. (2025) · Journal of Chemotherapy · doi:10.1080/1120009x.2025.2540172
Elgendy, S. O., Imam, M. S., Alshehri, A. A., Alsufyani, W. Z. A., Albogami, M., Almalki, S. A. S., Alkhaldi, M. N. M., Samarkandi, M. W. A., Alibrahim, D. T. Y., Hakami, F. A. H., et al. (2026) · BioMedInformatics · doi:10.3390/biomedinformatics6030028
Aly, A. S., Elmestiri, M., Yacoub, J., Yacoub, Z., Abulbida, S., & Idris, A. E. (2026) · Research Square · doi:10.21203/rs.3.rs-11431265/v1
- Authors
- Kiss, S., Gede, N., Hegyi, P., Nagy, B., Deák, R., Dembrovszky, F., Bunduc, S., Erőss, B., Leiner, T., Szakács, Z., & Alizadeh, H.
- Affiliations
- University of Szeged (HU)
- University of Pecs (HU)
- Semmelweis University (HU)
- Hinchingbrooke Hospital (GB)
- Corresponding author
- Alizadeh, Hussain
- ORCID
- Venue
- Scientific Reports
- Published
- 2021-11-09
- Volume
- 11
- Issue
- 1
- Pages
- 21916-21916
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC8578422
- OpenAlex
- W3213622034
- Cited by
- 23
- References
- 38
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 7 · 2023: 4 · 2022: 4
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund (ÚNKP-20-3)
- Economic Development and Innovation Operative Programme Grant (GINOP-2.3.4-15-2020-00010)
- Human Resources Development Operational Programme Grant (EFOP-3.6.1-16-2016-00004)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Keywords
- daratumumab, multiple myeloma, relapsed/refractory multiple myeloma, newly diagnosed multiple myeloma, minimal residual disease negativity, stringent complete response, complete response, disease progression, treatment safety, monoclonal antibody therapy
- MeSH terms
- Progression-Free Survival, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Multiple Myeloma, Randomized Controlled Trials as Topic, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
